BUSINESS STRATEGY

The strategy is to license out KT-110 to pharma company(ies) at the end of phase II. Example of deals closed in the addiction field:

Deal realized in 2011 in the field of the addiction

It concerns Biotie and Lundbeck companies for Selincro
( Nalmefene) at the end of 2011 in phase 2:

  • Upfront : 12 million euros
  • Milestones : 84 million euros
  • Royalties : not disclosed

Value at earlier stage
(enter into Phase I)
Indivior & Addex :
AD71441 (2018)

  • Upfront : 5 million d’euros
  • Milestones : 330 million d’euros

Last realized deal (2013)

It concerns XenoPort companies and Reckitt Benckiser for Arbaclofen in phase 2:

  • Upfront : 25 million USD
  • Milestones : 70 million USD + 50 million USD
  • Royalties : not disclosed